When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week
The structural issue is that pricing for most other medications (compounded tirzepatide, microdose options, oral formats) is hidden until the patient starts an intake quiz, and several pages require scheduling an appointment with a provider to see a quote at all
Some vendors provide first-order discounts of 10 to 15%
Capristo E, Panunzi S, De Gaetano A, Raffaelli M, Guidone C, Iaconelli A, et al